Chelsea Therapeutics Announces Reorganization Plan to Boost Stock Value

More news came out of Charlotte, N.C., Tuesday morning when beleaguered Chelsea Therapeutics (CHTP) announced its plans to undergo a complete reorganization of the company, which is to include layoffs, a new executive structure and changes to the Board of Directors, all with the long-term goal of developing more stockholder value, according to a press release.

The layoffs are expected to save the company $3.5 million in salaries over a year, and the layoffs should be completed by the end of the third quarter of 2012. Part of the plan includes not accepting any more patients for the company’s trial of the hypertension drug Northera, which should then produce results by the end of the year.

In other news, company founder, CEO and President Dr. Simon Pedder, announced that he was stepping down from the company effective immediately, and will serve only in an advisory capacity. The same is said for Keith Schmidt, vice president for marketing and sales, who is resigning his post but will remain an advisor to the company. During the search for a new CEO, Joseph G. Oliveto, VP for Operations for the last four years, will serve as interim CEO. In addition, three members of the Board of Directors (including Chairman Kevan Clemens) are stepping down.

While Chelsea is not widely held by hedge funds, this news may be very uncertain for Julian and Felix Baker’s Baker Bros. Advisors, which was invested nearly $5.9 million in Chelsea at the end of March. The next seven hedge funds combined were invested a total of less than $1 million.

“Chelsea Therapeutics has faced tremendous challenges in moving Northera forward through the regulatory process, making these difficult decisions necessary to ensure stockholder value is preserved in the short term and can be built over the long-term,” said Dr. Michael Weiser, the new Chairman of the Board in the wake of Clemens’ resignation, in a press release. ”We believe that this reorganization should allow the Company’s resources and capital to be laser-focused on efficient conclusion of the 306B study and the evaluation of next steps in the regulatory process. In tandem, the Board plans to explore and evaluate all available strategic options to determine the best path forward in the long-term strategic interests of the Company and its stockholders. We remain committed to Northera, a treatment which meets an important unmet need in patients and has a significant record of efficacy and safety in the clinic and in ex-U.S. markets. We would like to thank those employees leaving the Company for their service. We would also like to recognize Dr. Pedder’s years of dedication to Chelsea and his work in helping to advance the Company’s innovative therapies.”

blog comments powered by Disqus
Insider Monkey Headlines
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months Click to see monthly returns in table format!

Lists

6 Movies That You Should Watch to Better Understand The Cold War

Top 15 Best Paying Jobs for Women in 2014

Top 6 Things Rich People Do Differently Every Day

5 Retirement Mistakes To Avoid (and Einstein’s Famous Quote)

11 Smartest People in the World

6 Films About the Financial World You Need To Watch (While “The Wolf” is Not Around)

Warren Buffett and Billionaires Are Crazy About These 7 Stocks

The Top 10 States With Fastest Internet Speeds

10 Best Places to Visit in USA in August

Top 10 Cities to Visit Before You Die

Top 10 Genetically Modified Food In the US

15 Highest Grossing Movies Opening Weekend

5 Best Poker Books For Beginners

10 Strategies Hedge Funds Use to Make Huge Returns

Top 10 Fast Food Franchises to Buy

10 Best Places to Visit in Canada

Best Summer Jobs for Teachers

10 Youngest Hedge Fund Billionaires

Top 10 One Hit Wonders of the 90s

Fastest Growing Cities In America

Top 10 U.S. Cities for Freelancers

Top 9 Most Popular Free iPhone Apps

Top 10 Least Expensive Private Business Schools in the US

Top 15 Most Expensive Countries in the World – 2014

Top 6 Tax Scams and How to Protect Yourself

Top Businesses to Invest In

Top 5 Things You Might Be Doing Wrong With Your Business

Top 5 Strategic Technology Trends in 2014

Top Rags to Riches Stories

Parenting Behavior That Promotes Future Leaders

Top 5 Mistakes Made by Small Businesses

Top 5 Most Common and Potentially Devastating Financial Blunders

Top 5 Highest Paying Jobs for Web Designers

Top 6 Most Respected Professions that Also Pay Well

Top 5 Pitfalls Investors Should Avoid

Top 6 Lawyers and Policy Makers Under 30

Top 6 New Year’s Resolutions for Entrepreneurs

Top 7 Locations to Check in on Facebook

Top 5 Mistakes made by Rookie eBay Sellers

Top 7 eBook Publishers in 2013

Top 6 Health Industry Trends in 2014

5 Lessons for Entrepreneurs from Seth Godin

Top 5 Success Tips from Jordan Belfort – the Wolf of Wall Street

Best Master’s in Finance Degree Programs

Top 6 Earning Celebrities Over 50

The most expensive sports to play

Top 7 Earning Celebrities Under 25

Best 7 Online Courses to Take: Free Finance MOOCs

Top 6 Bad Habits that Promote Failure

20 Most Valuable Soccer Teams in the World in 2013

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!